Harvard Bioscience
HBIO
53 hedge funds and large institutions have $80.6M invested in Harvard Bioscience in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
49% more capital invested
Capital invested by funds: $54.2M → $80.6M (+$26.4M)
0.04% more ownership
Funds ownership: 6.14% → 6.18% (+0.04%)
12% less funds holding
Funds holding: 60 → 53 (-7)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$1.61M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$710K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$329K |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
+$253K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$235K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$856K |
| 2 |
WIC
Woodmont Investment Counsel
Nashville,
Tennessee
|
-$344K |
| 3 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$335K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$296K |
| 5 |
IAM
ICM Asset Management
Spokane,
Washington
|
-$275K |
HBIO Hedge Fund Activity: Q3 2017 in Review
53 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2017, worth a combined $80.6M — up 49% from $54.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HBIO and 5 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was First Light Asset Management, adding an estimated $1.61M. The largest seller was Jupiter Asset Management, exiting entirely with an estimated $856K sold.
- 53 institutional investors held Harvard Bioscience (HBIO) as of Q3 2017, down from 60 in Q2 2017.
- Funds reported $80.6M of Harvard Bioscience stock for Q3 2017, up 49% quarter-over-quarter.
- 5 funds opened new Harvard Bioscience positions in Q3 2017 and 12 closed out, a net change of -7 holders.
- The largest Harvard Bioscience buyer in Q3 2017 was First Light Asset Management, an estimated $1.61M added.
- The largest Harvard Bioscience seller in Q3 2017 was Jupiter Asset Management, an estimated $856K sold.
Based on aggregated 13F filings for Q3 2017.